Search
electroCore, Inc.
ECORAdd to Watchlist
6.270USD
-0.160-2.49%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
50.95MMarket Cap
LossP/E TTM
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D
Today
-2.49%
5 Days
-2.18%
1 Month
-6.14%
6 Months
+11.96%
Year to Date
+39.80%
1 Year
+16.11%
TradingKey Stock Score of electroCore, Inc.
Currency: USD Updated: 2026-05-15Key Insights
electroCore, Inc.'s fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 95 out of 206 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 21.46.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
electroCore, Inc.'s Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
electroCore, Inc. Highlights
StrengthsRisks
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company focused on improving health through its non-invasive vagus nerve stimulation (nVNS) technology platform and related product offerings. The Company’s portfolio also includes Quell, a wearable, app and cloud-enabled neuromodulation platform that is indicated for the treatment of fibromyalgia symptoms and lower-extremity chronic pain. Its product categories include handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headaches, and handheld, personal use consumer products. Its products include gammaCore, Quell Fibromyalgia, Truvaga and TAC-STIM. Its gammaCore Sapphire is a prescription medical device that is used for a variety of primary headache conditions. Truvaga is a personal-use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 99.83% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 32.03M.
Fairly Valued
The company’s latest PE is -3.54, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 923.46K shares, decreasing 26.43% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 54.49K shares of this stock.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
21.462
Target Price
+239.60%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
electroCore, Inc. News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
electroCore, Inc. Info
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company focused on improving health through its non-invasive vagus nerve stimulation (nVNS) technology platform and related product offerings. The Company’s portfolio also includes Quell, a wearable, app and cloud-enabled neuromodulation platform that is indicated for the treatment of fibromyalgia symptoms and lower-extremity chronic pain. Its product categories include handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headaches, and handheld, personal use consumer products. Its products include gammaCore, Quell Fibromyalgia, Truvaga and TAC-STIM. Its gammaCore Sapphire is a prescription medical device that is used for a variety of primary headache conditions. Truvaga is a personal-use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com.
Ticker SymbolECOR
CompanyelectroCore, Inc.
CEOGoldberger (Daniel S)
Websitehttps://www.electrocore.com/
Related Instruments
-1.32%
-2.23%
-1.62%
-0.49%
-1.30%
+0.41%
-1.57%
-2.22%
-1.05%
-1.04%
-1.59%
-3.29%
-1.06%
+0.04%
-0.76%
-0.71%
+1.31%
-1.21%
-1.39%
-0.56%Popular Instruments
102.160
+3.297 (+3.33%)
300.230
+2.020 (+0.68%)
225.320
-10.420 (-4.42%)
4538.710
-111.520 (-2.40%)
482.020
-7.101 (-1.45%)
1407.610
+24.890 (+1.80%)
724.660
-51.350 (-6.62%)
396.780
-4.290 (-1.07%)
77895.270
-335.730 (-0.43%)
422.240
-21.060 (-4.75%)
